Status:
UNKNOWN
14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
Lead Sponsor:
Kaohsiung Medical University
Conditions:
Helicobacter Pylori Eradication
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
1. Test for Helicobacter pylori. The test items include urease test, histology, bacterial culture, serology, and urea breath test. At least two positive results can be used to confirm the diagnosis. 2...
Detailed Description
Helicobacter pylori (H.pylori) infect more than 50% of humans globally. This study were (1) to test whether the efficacies of 14-day PCAB-based high-dose dual therapy and 14-day PPI-based reverse hybr...
Eligibility Criteria
Inclusion
- Subjects infected with Helicobacter pylori.
Exclusion
- Those who have ever received Helicobacter pylori sterilization treatment.
- Those who are allergic to the drugs used in this research.
- Those who have had stomach surgery.
- Those with severe liver cirrhosis or uremia or malignant tumors.
- Women who are pregnant or breastfeeding.
Key Trial Info
Start Date :
August 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
906 Patients enrolled
Trial Details
Trial ID
NCT05191888
Start Date
August 6 2021
End Date
December 31 2024
Last Update
January 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807